The US Food and Drug Administration (FDA) has approved a label update for Swiss pharma giant Novartis’ Leqvio (inclisiran), ...

The update was requested by the FDA based on data supporting the significant LDL-C lowering abilities of PCSK-targeting therapies.

The updated label no longer requires Leqvio (inclisiran) to be used in combination with statins for low-density lipoprotein ...

Novartis announced the FDA approved updated labeling for inclisiran, a small-interfering RNA therapy, for use as monotherapy ...

Novartis announced today that the US Food and Drug Administration (FDA) has approved a label update for Leqvio® (inclisiran), enabling its use as monotherapy along with diet and exercise to reduce low ...

Novartis reported an impressive 11% increase in sales in constant currency, accompanied by a 21% rise in core operating income for Q2 2025. This growth underscores the company’s strong financial ...

Q2 2025 Earnings Call Transcript July 21, 2025 Operator: Good morning and good afternoon, and welcome to the Novartis Q2 2025 ...

Swiss pharma giant Novartis AGNVS reported better-than-expected results for the second quarter of 2025 and upped annual guidance for core operating income. Core earnings (excluding one-time charges) ...

Novartis is a “pure-play” innovative medicines company ... CML and continued strong momentum from the recently launched early-line indication in the US Leqvio (USD 298 million, +61% cc) continued ...

Novartis’ anti-inflammatory antibody Cosentyx failed to improve remission in a Phase III trial of giant cell arteritis, dealing a blow to the pharma’s aspirations of challenging AbbVie’s Rinvoq in ...

Novartis/Alnylam Pharmaceuticals' LEQVIO (inclisiran) Overview LEQVIO (inclisiran) is a first-of-its-kind therapy developed by Novartis based on small interfering RNA (siRNA) technology.